. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Cancer Res. 2018 May 29;78(15):4360–4369. doi: 10.1158/0008-5472.CAN-17-3124

Table 1.

The combination of abemaciclib and altiratinib

	Cytotoxicity/Bliss Difference Bliss Difference								Bliss Difference
Altiratinib (μM)	25%	31%/2%	39%/5%	51%/14%	68%/27%	80%/33%	100%/30%		>30%
	4%	23%/5%	31%/7%	38%/10%	46%/14%	66%/26%	92%/26%		20-30%
	10%	17%/3%	27%/6%	33%/9%	40%/11%	54%/17%	88%/24%	G88	10-20%
	7%	13%/1%	23%/5%	29%/7%	36%/10%	42%/7%	81%/18%		0-10%
	0%	5%	12%	16%	21%	30%	60%
	Abemaciclib (μM)

Altiratinib (μM)	20%	41%/17%	50%/20%	60%/26%	81%/38%	90%/40%	100%
	11%	32%/16%	41%/19%	49%/22%	63%/26%	75%/30%	100%
	8%	24%/11%	33%/14%	41%/16%	51%/16%	65%/22%	100%	G528
	5%	16%/5.3%	24%/8%	35%/13%	44%/11%	56%/15%	100%
	0%	6%	12%	18%	29%	38%	100%
	Abemaciclib (μM)

Cytotoxicity and synergy scores of the combination of abemaciclib and altiratinib in two GIC lines calculated with the Bliss method. Increasing doses of each agent provided higher cytotoxicity and better Bliss difference (first number shown is observed cell death; second number is observed cell death minus expected death=Bliss difference).